6446.TW PharmaEssentia
- Market cap
- TWD 525B
- P/E
- 73.1x
- P/B
- 14.27x
- ROE
- 22.3%
- Dividend yield
- 0.07%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is 6446.TW undervalued?
Graham numberThe Graham number of PharmaEssentia cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PharmaEssentia fundamental analysis
No fundamental analysis for PharmaEssentia yet.
PharmaEssentia stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PharmaEssentia
PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; N…
Full company profilePharmaEssentia financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PharmaEssentia annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.47M | 4.04M | 26.2M | 306M | 557M | 657M | 2.88B | 5.11B | 9.73B | 15.6B | 22.5B |
| Gross Profit | 4.34M | 4.30M | -2.16M | 244M | 184M | 278M | 2.07B | 4.50B | 8.56B | 13.7B | 20.2B |
| Operating Income | -849M | -889M | -1.05B | -849M | -1.72B | -2.82B | -2.03B | -1.91B | 1.74B | 4.93B | 9.07B |
| EBITDA | -779M | -807M | -979M | -697M | -1.76B | -2.57B | -1.60B | -671M | 3.38B | 5.41B | 10.5B |
| Net Income | -845M | -872M | -1.04B | -843M | -1.95B | -2.81B | -1.37B | -624M | 2.97B | 5.05B | 8.21B |
| EPS | -3.63 | -3.51 | -4.17 | -3.43 | -7.16 | -9.74 | -4.36 | -1.74 | 8.17 | 14 | 20 |
| Balance Sheet | |||||||||||
| Total Assets | 4.50B | 3.67B | 2.81B | 2.96B | 5.53B | 6.20B | 15.3B | 27.3B | 31.1B | 37.4B | 44.1B |
| Total Liabilities | 228M | 212M | 333M | 704M | 1.61B | 1.95B | 3.19B | 3.32B | 3.59B | 5.44B | 7.29B |
| Shareholders' Equity | 4.27B | 3.46B | 2.47B | 2.26B | 3.92B | 4.25B | 12.1B | 23.9B | 27.5B | 32.0B | 36.8B |
| Cash & Short-term Investments | 4.05B | 3.19B | 2.17B | 1.40B | 3.21B | 3.45B | 10.3B | 19.7B | 21.1B | 22.7B | 24.5B |
| Total Debt | 112M | 106M | 100.0M | 425M | 647M | 536M | 1.57B | 1.20B | 965M | 856M | 1.02B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -657M | -790M | -827M | -945M | -1.46B | -2.46B | -1.51B | -706M | 2.55B | 5.28B | 8.06B |
| Capital Expenditure | 25.7M | 28.2M | 151M | 121M | 208M | 97.9M | 321M | 1.33B | 903M | 1.91B | 2.65B |
| Free Cash Flow | -683M | -819M | -978M | -1.07B | -1.66B | -2.56B | -1.83B | -2.03B | 1.64B | 3.37B | 5.41B |
| Ratios | |||||||||||
| ROE | -19.8% | -25.2% | -42.1% | -37.4% | -49.7% | -66.1% | -11.3% | -2.6% | 10.8% | 15.8% | 22.3% |
| ROA | -18.8% | -23.8% | -37.1% | -28.5% | -35.2% | -45.4% | -9.0% | -2.3% | 9.5% | 13.5% | 18.6% |
| Net Profit Margin | -15,437.9% | -21,618.5% | -3,963.1% | -275.8% | -349.6% | -428.2% | -47.7% | -12.2% | 30.5% | 32.3% | 36.5% |
| Debt to Equity | 0.03x | 0.03x | 0.04x | 0.19x | 0.17x | 0.13x | 0.13x | 0.05x | 0.04x | 0.03x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
PharmaEssentia dividends
- Dividend yield
- 0.07%
- Forward dividend
- 1.49 TWD
- Payout ratio
- 7.3%
- Ex-dividend date
- Jul 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 366M | 0.99 | 7.3% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1109.2778:1000 on Jul 9, 2026.
Who owns PharmaEssentia
- Insiders 12.40%
- Institutions 22.27%
- Public & others 65.33%
- Shares outstanding 414M
- Free float 331M
PharmaEssentia company profile
- Company name
- PharmaEssentia
- Ticker
- 6446.TW
- ISIN
- TW0006446008
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Fiscal year end
- September
- Address
- No. 3, Park Street, Taipei, Taiwan, 115
- Phone
- 886 2 2655 7688
- Website
- pharmaessentia.com
About PharmaEssentia
PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and immunology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
PharmaEssentia management
10- Dr. Ching-Leou Teng Ph.D.Chairman & Chief Pharmaceutical Officer
- Mr. Ko-Chung Lin Ph.D.Founder, CEO, Chief Strategy Officer & Director
- Mr. Chan-Kou Hwang Ph.D.President, GM & Director
- Ms. Snow ChangSenior Director of Finance
- Mr. Samuel LinVP and Head of Business Operations & Strategy
- Xue Ling ZhangAccounting Supervisor
- Ms. Lih-Ling Lin Ph.D.Chief Scientific Officer
- Hsing-I ChenGeneral Counsel
- Dr. Albert Qin M.D., Ph.D.Chief Medical Officer
- Narihisa MiyachiHead of Japan Medical Affairs